Nurami Medical
Nurami Medical is dedicated to modernizing soft tissue surgical repair through innovative nanofiber and biomaterial technologies. The company develops bio surgical implants that promote healing and address complications associated with current soft tissue implants, aiming to revolutionize internal soft tissue repair globally.
Industries
Nr. of Employees
small (1-50)
Nurami Medical
36 Ha-Namal St., Haifa, Israel
Patents
Products
ArtiFascia
A multilayer resorbable dural repair graft combining a porous nanofiber scaffold and an integrated thin film designed to provide watertight closure and support dura regeneration; reported clearance for sale in the US under FDA 510(k).
ArtiFascia
A multilayer resorbable dural repair graft combining a porous nanofiber scaffold and an integrated thin film designed to provide watertight closure and support dura regeneration; reported clearance for sale in the US under FDA 510(k).
Services
Distribution and sale of multilayer dural repair grafts for cranial and spinal surgical procedures in markets where cleared/authorized.
Distribution and sale of multilayer dural repair grafts for cranial and spinal surgical procedures in markets where cleared/authorized.
Expertise Areas
- Soft tissue regeneration
- Dural repair and neurosurgical implants
- Electrospinning and nanofiber engineering
- Biomaterials development and resorbable polymers
Key Technologies
- Electrospinning
- Nanofiber scaffolds
- Bioresorbable polymers
- Multilayer thin-film sealing
News & Updates
Nurami showcased its FDA-cleared ArtiFascia at the CNS 2022 congress in San Francisco.
Nurami will participate in the AANS 2025 conference in Boston, April 25-28, 2025.
Nurami will participate in the NASBS 2025 conference in New Orleans, February 13-16, 2025.
Nurami's ArtiFascia® has received FDA 510(k) clearance following successful clinical trials, making it available for sale in the US.
Dr. Henry Brem, a renowned neurosurgeon from Johns Hopkins University, has joined Nurami's scientific advisory board in May 2019.
Impact fund Iron Nation has invested in Nurami Medical, marking one of its first investments.
Nurami showcased its FDA-cleared ArtiFascia at the CNS 2022 congress in San Francisco.
Nurami will participate in the AANS 2025 conference in Boston, April 25-28, 2025.
Nurami will participate in the NASBS 2025 conference in New Orleans, February 13-16, 2025.
Nurami's ArtiFascia® has received FDA 510(k) clearance following successful clinical trials, making it available for sale in the US.
Dr. Henry Brem, a renowned neurosurgeon from Johns Hopkins University, has joined Nurami's scientific advisory board in May 2019.
Impact fund Iron Nation has invested in Nurami Medical, marking one of its first investments.